{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:10:24Z","timestamp":1794568224424,"version":"4.9.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG2J0221-2, CMRPG3L0491, CMRPG3I0381-2, CIRPG3I0024-5, CIRPG3I0044-5, CIRPG2I0014-5, OMRPG3N0011"],"award-info":[{"award-number":["CMRPG2J0221-2, CMRPG3L0491, CMRPG3I0381-2, CIRPG3I0024-5, CIRPG3I0044-5, CIRPG2I0014-5, OMRPG3N0011"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54180-7","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T15:29:50Z","timestamp":1735572590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-4235","authenticated-orcid":false,"given":"Chun-Bing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuen-Iu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Wen-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Keng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Hui-Kang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chuan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-4008","authenticated-orcid":false,"given":"Wei-Ti","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Yin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Hsuan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Yu-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline Chung-Yee","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Mei","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Kai","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaw-Ning","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chih","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Jen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jr","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lung","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-4129","authenticated-orcid":false,"given":"Chuang-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1681-0959","authenticated-orcid":false,"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"54180_CR1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"54180_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908\u2013918 (2015).","journal-title":"Lancet Oncol."},{"key":"54180_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375\u2013384 (2015).","journal-title":"Lancet Oncol."},{"key":"54180_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamaoncol.2019.0413","volume":"5","author":"D Davar","year":"2019","unstructured":"Davar, D. & Kirkwood, J. M. PD-1 immune checkpoint inhibitors and immune-related adverse events: understanding the upside of the downside of checkpoint blockade. JAMA Oncol. 5, 942\u2013943 (2019).","journal-title":"JAMA Oncol."},{"key":"54180_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Prim. 6, 38 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"54180_CR6","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41591-022-02095-5","volume":"28","author":"CA Taylor","year":"2022","unstructured":"Taylor, C. A. et al. IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28, 2592\u20132600 (2022).","journal-title":"Nat. Med."},{"key":"54180_CR7","doi-asserted-by":"crossref","unstructured":"Kumar, V. et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front. Pharmacol. 8, 49 (2017).","DOI":"10.3389\/fphar.2017.00311"},{"key":"54180_CR8","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/CMAR.S163391","volume":"10","author":"CB Chen","year":"2018","unstructured":"Chen, C. B. et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag. Res. 10, 1259\u20131273 (2018).","journal-title":"Cancer Manag. Res."},{"key":"54180_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","volume":"44","author":"JL Curry","year":"2017","unstructured":"Curry, J. L. et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J. Cutan. Pathol. 44, 158\u2013176 (2017).","journal-title":"J. Cutan. Pathol."},{"key":"54180_CR10","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips, G. S. et al. Treatment outcomes of immune-related cutaneous adverse events. J. Clin. Oncol. 37, 2746\u20132758 (2019).","journal-title":"J. Clin. Oncol."},{"key":"54180_CR11","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","volume":"331","author":"JC Roujeau","year":"1994","unstructured":"Roujeau, J. C. & Stern, R. S. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331, 1272\u20131285 (1994).","journal-title":"N. Engl. J. Med."},{"key":"54180_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","volume":"10","author":"SI Hung","year":"2024","unstructured":"Hung, S. I. et al. Severe cutaneous adverse reactions. Nat. Rev. Dis. Prim. 10, 30 (2024).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"54180_CR13","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","volume":"24","author":"E Raschi","year":"2019","unstructured":"Raschi, E. et al. Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. Food and Drug Administration adverse event reporting system. Oncologist 24, e1228\u2013e1231 (2019).","journal-title":"Oncologist"},{"key":"54180_CR14","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","volume":"333","author":"JC Roujeau","year":"1995","unstructured":"Roujeau, J. C. et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600\u20131607 (1995).","journal-title":"N. Engl. J. Med."},{"key":"54180_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1071","volume":"105","author":"YH Wang","year":"2019","unstructured":"Wang, Y. H. et al. The medication risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in Asians: the major drug causality and comparison with the US FDA label. Clin. Pharm. Ther. 105, 112\u2013120 (2019).","journal-title":"Clin. Pharm. Ther."},{"key":"54180_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nature11147","volume":"486","author":"PT Illing","year":"2012","unstructured":"Illing, P. T. et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486, 554\u2013558 (2012).","journal-title":"Nature"},{"key":"54180_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpt.683","volume":"102","author":"RY Pan","year":"2017","unstructured":"Pan, R. Y., Dao, R. L., Hung, S. I. & Chung, W. H. Pharmacogenomic advances in the prediction and prevention of cutaneous idiosyncratic drug reactions. Clin. Pharm. Ther. 102, 86\u201397 (2017).","journal-title":"Clin. Pharm. Ther."},{"key":"54180_CR18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"WH Chung","year":"2004","unstructured":"Chung, W. H. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).","journal-title":"Nature"},{"key":"54180_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","volume":"151","author":"A Gibson","year":"2023","unstructured":"Gibson, A. et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J. Allergy Clin. Immunol. 151, 289\u2013300.e284 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"54180_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jama.2014.7859","volume":"312","author":"WH Chung","year":"2014","unstructured":"Chung, W. H. et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312, 525\u2013534 (2014).","journal-title":"JAMA"},{"key":"54180_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","volume":"147","author":"CW Wang","year":"2021","unstructured":"Wang, C. W. et al. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. J. Allergy Clin. Immunol. 147, 1402\u20131412 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"54180_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12929-022-00845-8","volume":"29","author":"H Jiang","year":"2022","unstructured":"Jiang, H. et al. Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity. J. Biomed. Sci. 29, 58 (2022).","journal-title":"J. Biomed. Sci."},{"key":"54180_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"WH Chung","year":"2008","unstructured":"Chung, W. H. et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14, 1343\u20131350 (2008).","journal-title":"Nat. Med."},{"key":"54180_CR24","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.jaip.2020.09.048","volume":"9","author":"CB Chen","year":"2021","unstructured":"Chen, C. B. et al. Detecting lesional granulysin levels for rapid diagnosis of cytotoxic T lymphocyte-mediated bullous skin disorders. J. Allergy Clin. Immunol. Pr. 9, 1327\u20131337.e1323 (2021).","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"54180_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaci.2013.04.036","volume":"132","author":"CW Wang","year":"2013","unstructured":"Wang, C. W. et al. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. J. Allergy Clin. Immunol. 132, 713\u2013722.e711 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"54180_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"54180_CR27","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36, 1714\u20131768 (2018).","journal-title":"J. Clin. Oncol."},{"key":"54180_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","volume":"65","author":"Y Yamane","year":"2016","unstructured":"Yamane, Y. et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients\u2014treatment and outcome. Allergol. Int. 65, 74\u201381 (2016).","journal-title":"Allergol. Int."},{"key":"54180_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson, J. A. et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J. Natl Compr. Cancer Netw. 18, 230\u2013241 (2020).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"54180_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1795-z","volume":"20","author":"T Abdelaal","year":"2019","unstructured":"Abdelaal, T. et al. A comparison of automatic cell identification methods for single-cell RNA sequencing data. Genome Biol. 20, 194 (2019).","journal-title":"Genome Biol."},{"key":"54180_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"54180_CR32","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","volume":"178","author":"JC Martin","year":"2019","unstructured":"Martin, J. C. et al. Single-cell analysis of Crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. Cell 178, 1493\u20131508.e1420 (2019).","journal-title":"Cell"},{"key":"54180_CR33","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655\u2013671.e622 (2020).","journal-title":"Cell"},{"key":"54180_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","volume":"178","author":"CS Smillie","year":"2019","unstructured":"Smillie, C. S. et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell 178, 714\u2013730.e722 (2019).","journal-title":"Cell"},{"key":"54180_CR35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1172\/JCI42280","volume":"120","author":"H Matsushima","year":"2010","unstructured":"Matsushima, H. & Takashima, A. Bidirectional homing of Tregs between the skin and lymph nodes. J. Clin. Invest. 120, 653\u2013656 (2010).","journal-title":"J. Clin. Invest."},{"key":"54180_CR36","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/bioinformatics\/btt285","volume":"29","author":"W Luo","year":"2013","unstructured":"Luo, W. & Brouwer, C. Pathview: an R\/Bioconductor package for pathway-based data integration and visualization. Bioinformatics 29, 1830\u20131831 (2013).","journal-title":"Bioinformatics"},{"key":"54180_CR37","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","volume":"168","author":"JH Dufour","year":"2002","unstructured":"Dufour, J. H. et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168, 3195\u20133204 (2002).","journal-title":"J. Immunol."},{"key":"54180_CR38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4049\/jimmunol.1901046","volume":"204","author":"KL Chu","year":"2020","unstructured":"Chu, K. L., Batista, N. V., Girard, M. & Watts, T. H. Monocyte-derived cells in tissue-resident memory T cell formation. J. Immunol. 204, 477\u2013485 (2020).","journal-title":"J. Immunol."},{"key":"54180_CR39","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jid.2019.11.020","volume":"140","author":"JA Trubiano","year":"2020","unstructured":"Trubiano, J. A. et al. Analysis of skin-resident memory T cells following drug hypersensitivity reactions. J. Invest. Dermatol. 140, 1442\u20131445.e1444 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"54180_CR40","doi-asserted-by":"publisher","unstructured":"Villani, A. P. et al. Massive clonal expansion of polycytotoxic skin and blood CD8(+) T cells in patients with toxic epidermal necrolysis. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abe0013 (2021).","DOI":"10.1126\/sciadv.abe0013"},{"key":"54180_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654190","volume":"12","author":"EM Schunkert","year":"2021","unstructured":"Schunkert, E. M., Shah, P. N. & Divito, S. J. Skin resident memory T cells may play critical role in delayed-type drug hypersensitivity reactions. Front Immunol. 12, 654190 (2021).","journal-title":"Front Immunol."},{"key":"54180_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.iac.2022.01.002","volume":"42","author":"CW Wang","year":"2022","unstructured":"Wang, C. W., Divito, S. J., Chung, W. H. & Hung, S. I. Advances in the pathomechanisms of delayed drug hypersensitivity. Immunol. Allergy Clin. North Am. 42, 357\u2013373 (2022).","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"54180_CR43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s43018-021-00180-1","volume":"2","author":"J Han","year":"2021","unstructured":"Han, J. et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat. Cancer 2, 300\u2013311 (2021).","journal-title":"Nat. Cancer"},{"key":"54180_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","volume":"28","author":"AX Lozano","year":"2022","unstructured":"Lozano, A. X. et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28, 353\u2013362 (2022).","journal-title":"Nat. Med."},{"key":"54180_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri2526","volume":"9","author":"M Croft","year":"2009","unstructured":"Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271\u2013285 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"54180_CR46","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","volume":"29","author":"MA Perazella","year":"2018","unstructured":"Perazella, M. A. & Shirali, A. C. Nephrotoxicity of cancer immunotherapies: past, present and future. J. Am. Soc. Nephrol. 29, 2039\u20132052 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"54180_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/pcmr.12667","volume":"31","author":"M Abdallah","year":"2018","unstructured":"Abdallah, M. et al. CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: a multicenter cross-sectional study. Pigment Cell Melanoma Res. 31, 330\u2013336 (2018).","journal-title":"Pigment Cell Melanoma Res."},{"key":"54180_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","volume":"120","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br. J. Cancer 120, 63\u201368 (2019).","journal-title":"Br. J. Cancer"},{"key":"54180_CR49","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","volume":"66","author":"MS von Itzstein","year":"2020","unstructured":"von Itzstein, M. S., Khan, S. & Gerber, D. E. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin. Chem. 66, 779\u2013793 (2020).","journal-title":"Clin. Chem."},{"key":"54180_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11396-2","volume":"10","author":"RY Pan","year":"2019","unstructured":"Pan, R. Y. et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nat. Commun. 10, 3569 (2019).","journal-title":"Nat. Commun."},{"key":"54180_CR51","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","volume":"128","author":"CW Wang","year":"2018","unstructured":"Wang, C. W. et al. Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. J. Clin. Invest 128, 985\u2013996 (2018).","journal-title":"J. Clin. Invest"},{"key":"54180_CR52","doi-asserted-by":"publisher","unstructured":"Kinoshita, M. et al. Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aax2398 (2021).","DOI":"10.1126\/scitranslmed.aax2398"},{"key":"54180_CR53","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","volume":"147","author":"B Husain","year":"2021","unstructured":"Husain, B. et al. Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J. Cancer Res. Clin. Oncol. 147, 1623\u20131630 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"54180_CR54","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","volume":"22","author":"M Mandai","year":"2016","unstructured":"Mandai, M. et al. Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin. Cancer Res. 22, 2329\u20132334 (2016).","journal-title":"Clin. Cancer Res."},{"key":"54180_CR55","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428\u2013432 (2019).","journal-title":"Nature"},{"key":"54180_CR56","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3389\/fimmu.2019.01818","volume":"10","author":"A Montfort","year":"2019","unstructured":"Montfort, A. et al. The TNF paradox in cancer progression and immunotherapy. Front Immunol. 10, 1818 (2019).","journal-title":"Front Immunol."},{"key":"54180_CR57","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","volume":"27","author":"A Montfort","year":"2021","unstructured":"Montfort, A. et al. Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin. Cancer Res. 27, 1037\u20131047 (2021).","journal-title":"Clin. Cancer Res."},{"key":"54180_CR58","doi-asserted-by":"publisher","unstructured":"Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-002435 (2021).","DOI":"10.1136\/jitc-2021-002435"},{"key":"54180_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.17039","volume":"51","author":"TK Satoh","year":"2024","unstructured":"Satoh, T. K., Neulinger, M. M., Stadler, P. C., Aoki, R. & French, L. E. Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications. J. Dermatol. 51, 3\u201311 (2024).","journal-title":"J. Dermatol."},{"key":"54180_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","volume":"209","author":"JC Roujeau","year":"2005","unstructured":"Roujeau, J. C. Clinical heterogeneity of drug hypersensitivity. Toxicology 209, 123\u2013129 (2005).","journal-title":"Toxicology"},{"key":"54180_CR61","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","volume":"138","author":"A Auquier-Dunant","year":"2002","unstructured":"Auquier-Dunant, A. et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch. Dermatol. 138, 1019\u20131024 (2002).","journal-title":"Arch. Dermatol"},{"key":"54180_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.5414\/ALX01508E","volume":"1","author":"M Mockenhaupt","year":"2017","unstructured":"Mockenhaupt, M. Epidemiology of cutaneous adverse drug reactions. Allergol. Sel. 1, 96\u2013108 (2017).","journal-title":"Allergol. Sel."},{"key":"54180_CR63","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377\u20132385 (2017).","journal-title":"Ann. Oncol."},{"key":"54180_CR64","doi-asserted-by":"publisher","first-page":"e1911519","DOI":"10.1001\/jamanetworkopen.2019.11519","volume":"2","author":"D Hsiehchen","year":"2019","unstructured":"Hsiehchen, D., Watters, M. K., Lu, R., Xie, Y. & Gerber, D. E. Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors. JAMA Netw. Open 2, e1911519 (2019).","journal-title":"JAMA Netw. Open"},{"key":"54180_CR65","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","volume":"49","author":"B Rzany","year":"1996","unstructured":"Rzany, B. et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J. Clin. Epidemiol. 49, 769\u2013773 (1996).","journal-title":"J. Clin. Epidemiol."},{"key":"54180_CR66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas, B. et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin. Pharm. Ther. 88, 60\u201368 (2010).","journal-title":"Clin. Pharm. Ther."},{"key":"54180_CR67","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo, C. A. et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30, 239\u2013245 (1981).","journal-title":"Clin. Pharmacol. Ther."},{"key":"54180_CR68","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"54180_CR69","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"54180_CR70","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nbt.4091","volume":"36","author":"L Haghverdi","year":"2018","unstructured":"Haghverdi, L., Lun, A. T. L., Morgan, M. D. & Marioni, J. C. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol. 36, 421\u2013427 (2018).","journal-title":"Nat. Biotechnol."},{"key":"54180_CR71","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cell.2018.08.067","volume":"175","author":"J Kinchen","year":"2018","unstructured":"Kinchen, J. et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell 175, 372\u2013386.e317 (2018).","journal-title":"Cell"},{"key":"54180_CR72","doi-asserted-by":"publisher","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/nbt.4314 (2018).","DOI":"10.1038\/nbt.4314"},{"key":"54180_CR73","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e324 (2019).","journal-title":"Cell Syst."},{"key":"54180_CR74","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"54180_CR75","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"54180_CR76","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"54180_CR77","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979\u2013982 (2017).","journal-title":"Nat. Methods"},{"key":"54180_CR78","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381\u2013386 (2014).","journal-title":"Nat. Biotechnol."},{"key":"54180_CR79","doi-asserted-by":"crossref","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","DOI":"10.1038\/s41467-021-21246-9"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54180-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54180-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54180-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T04:58:35Z","timestamp":1735621115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54180-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54180"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54180-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10733"}}